CSF3 and neoplasm: This experience reminds us that: 1For similar high-risk patients, prophylactic use of G-CSF after the first cycle of chemotherapy may be considered to reduce the risk of FN (34); 2Comprehensive education on post-chemotherapy self-management must be provided to patients and their families; 3Blood counts should be closely monitored during subsequent treatment cycles, with readiness for prompt and robust supportive care to ensure treatment safety and adherence, thereby optimizing the comprehensive tumor management model.